What is Recombinetics?
Recombinetics operates at the intersection of biotechnology and precision agriculture, specializing in sophisticated animal gene editing. The company is widely recognized for its development of custom gene-edited swine models, which serve as critical assets for preclinical research and regenerative medicine. By providing high-fidelity biological tools, Recombinetics enables researchers to reduce their reliance on nonhuman primates, thereby accelerating the pace of medical discovery. Furthermore, the firm applies its proprietary gene-editing platform to enhance animal health and sustainability, addressing core challenges within the global agricultural sector. Through a commitment to integrity-driven innovation, the organization maintains a robust portfolio of services that cater to both healthcare institutions and commercial agricultural enterprises.
How much funding has Recombinetics raised?
Recombinetics has raised a total of $69.8M across 10 funding rounds:
Private Equity
$540K
Private Equity
$5.7M
Multiple Rounds
$19.3M
Debt
$7M
Private Equity
$2.1M
Series A
$34M
Debt
$350K
Debt
$766K
Private Equity (2014): $540K, investors not publicly disclosed
Private Equity (2015): $5.7M, investors not publicly disclosed
Private Equity (2016): $630K, investors not publicly disclosed
Unspecified (2016): $7.7M, investors not publicly disclosed
Private Equity (2016): $11M, investors not publicly disclosed
Debt (2017): $7M, investors not publicly disclosed
Private Equity (2017): $2.1M, investors not publicly disclosed
Series A (2018): $34M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $766K backed by PPP
Key Investors in Recombinetics
Undisclosed Investor
An undisclosed investor participating in the funding round, providing essential capital to support the company's long-term strategic objectives.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round, contributing to the firm's ongoing development in the gene-editing sector.
What's next for Recombinetics?
With the recent infusion of capital, Recombinetics is well-positioned to scale its operational capacity and expand its research and development pipeline. The strategic focus will likely shift toward deepening its footprint in the biomedical research market while simultaneously exploring new commercial applications for its gene-editing technology in livestock production. As the regulatory environment for gene-edited organisms continues to evolve, the company is expected to prioritize compliance and ethical standards to maintain its competitive advantage. Future growth initiatives will likely involve enhancing its proprietary platform to support more complex genetic modifications, thereby increasing the value proposition for its diverse client base in the life sciences and agricultural industries.
See full Recombinetics company page
